$QTTB 8-K SEC Filings

Filed On	Filing
30 Sep 2026	8-K: Regulation FD Disclosure; Other Events Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
14 Sep 2026	8-K: Regulation FD Disclosure; Other Events Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
05 Aug 2026	8-K: Results of Operations and Financial Condition
15 Jul 2026	8-K: Entry into a Material Definitive Agreement
13 Jul 2026	8-K: Other Events
13 Jul 2026	8-K: Regulation FD Disclosure; Other Events
16 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
27 May 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
05 May 2026	8-K: Results of Operations and Financial Condition
24 Apr 2026	8-K: Other Events
27 Mar 2026	8-K: Entry into a Material Definitive Agreement
10 Mar 2026	8-K: Results of Operations and Financial Condition
17 Feb 2026	8-K: Entry into a Material Definitive Agreement; Other Events
19 Dec 2025	8-K: Departure/Election of Directors or Officers; Compensation
01 Dec 2025	8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
13 Nov 2025	8-K: Results of Operations and Financial Condition
21 Oct 2025	8-K: Other Events
06 Aug 2025	8-K: Results of Operations and Financial Condition
25 Jun 2025	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
17 Jun 2025	8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Comments